Alira Health advised Ipsen in the Acquisition of Akkadeas Pharma


Alira Health advised Ipsen in the Acquisition of Akkadeas Pharma

February 6, 2017

Paris, France – February 6, 2017 – Ipsen announced that it has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future. Akkadeas Pharma will become Ipsen’s Italian distributor for Smecta (Diosmectal). “This strategic transaction will allow Ipsen’s Primary Care business to strengthen its presence in Italy, a key European country for the business unit. It represents an attractive opportunity to accelerate Ipsen’s Primary Care business, bringing in an established commercial infrastructure to distribute Smecta and generate instant incremental revenue, with the potential to further leverage as the market develops” stated Jean Fabre, Executive Vice President Primary Care of Ipsen. 

Alira Health acted as an M&A and financial advisor for Ipsen.


Ipsen is a global specialty driven pharmaceutical company with a significant presence in primary care. Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in over 30 countries worldwide. The Group has more than 4,600 employees all over the world.



Akkadeas Pharma is a privately-held consumer health care company in Italy with a diversified gastrointestinal-focused portfolio including probiotics, medical devices and food supplements. The drugs and the food supplements originate from highly specialized companies through commercial agreements or from the company’s own development and ideas. The manufacturing of the products is done by toll manufacturers known for their elevated standards and quality.



Founded in 1999, Alira Health, formerly known as CMC Consulting Group, provides integrated strategy, execution and innovation services to help businesses bring pharma, medical technology and healthcare IT to market. We are an international advisory firm with offices in six locations across the United States and Europe, including Boston, San Francisco, Munich, Paris, Milan and Barcelona. The company’s team is composed of consultants, bankers, doctors and scientists who help clients maximize investment, market and clinical opportunities through every phase of the business and product life cycle.